ACRS News and Press, Aclaris Therapeutics Inc. From 11/04/20

First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis Initiated Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, for the Treatment of Cr...

Aclaris Therapeutics (ACRS) has dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate to severe atopic dermatitis.ATI-1777 is an investigational topical “soft” Janus kinase 1/3 inhibitor, and was developed internally utili...

WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris’ Phase 2a...

Gainers: [[AKBA]] +8%. [[FATE]] +5%. [[CHMA]] +3.5%. [[UAVS]] +3%. [[ZAGG]] +2%.Losers: [[KLIC]] -5.1%. [[ACRS]] -4.6%. [[LITB]] -2.9%. [[CORR]] -2.6%. [[DPW]] -1.3%. For further details see: CORR, FATE, AKBA and DPW among after-hours movers

Gainers: Precigen (PGEN) +26%. Medigus (MDGS) +24%. Aclaris Therapeutics (ACRS) +17%. cbdMD (YCBD) +15%. Abeona Therapeutics (ABEO) +12%.Losers: Mallinckrodt (MNK) -18%. GeoVax Labs (GOVX) -13%. AgeX Therapeutics (AGE) -12%. COMPASS Pathways (CMPS) -9%. ThermoGen...

Will These High Volume Penny Stocks Make Higher Highs This Month? One of the quickest ways to find penny stocks is by looking at technical trends. As I’ve said in the past, sometimes volume and price will dictate momentum before fundamentals. While that type of action could stem from...

Aclaris Therapeutics (NASDAQ: ACRS ) : Q2 GAAP EPS of -$0.28 beats by $0.07 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WAYNE, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2020 and provide...

Gainers:  Immuron (NASDAQ: IMRN )   +121% . More news on: Immuron Limited, DPW Holdings, Inc., iBio, Inc., Stocks on the move, , Read more ...

Aclaris Therapeutics has submitted an Investigational New Drug application to the FDA for ATI-1777, a topical "soft" Janus kinase 1/3 inhibitor, for moderate to severe atopic dermatitis (AD). More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Read more ...